RARE Ultragenyx Pharmaceutical Inc.

NASDAQ
$17.73

Ultragenyx Pharmaceutical Inc. (RARE) is expected to report earnings on February 2, 2027, after the market close. The consensus earnings estimate is $0.86 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.1% since its last earnings release on November 3, 2026.

Ultragenyx Pharmaceutical Missed Consensus Estimates, Reaffirms Revenue Guidance
Tuesday, November 3, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 2
Tuesday · 4:00 PM ET
Earnings Whisper
-
vs $0.86
Rev est $226.16M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $16.28

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a development-stage biopharmaceutical company engaged in identifying, acquiring, developing and marketing novel products for the treatment of rare and ultra-rare disease.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.